Patents by Inventor Prasanna Savanor Maddu Rao

Prasanna Savanor Maddu Rao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclic ureas as inhibitors of rock
    Patent number: 10123993
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: November 13, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter W. Glunz, Doree F. Sitkoff, Navnath Dnyanoba Yadav, Mandar Shrikrishna Bodas, Rajeev S. Bhide, Sharanabasappa Patil, Kumaresan Chinnakotti, Prasanna Savanor Maddu Rao, Jeevan Prakash Shetty
  • Lactams as inhibitors of rock
    Patent number: 10112929
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: October 30, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter W. Glunz, Doree F. Sitkoff, Mandar Shrikrishna Bodas, Navnath Dnyanoba Yadav, Sharanabasappa Patil, Prasanna Savanor Maddu Rao
  • LACTAMS AS INHIBITORS OF ROCK
    Publication number: 20180044326
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: March 8, 2016
    Publication date: February 15, 2018
    Applicant: Bristol-Myers Squibb Comapany
    Inventors: Peter W. Glunz, Doree F. Sitkoff, Mandar Shrikrishna Bodas, Navnath Dnyanoba Yadav, Sharanabasappa Patil, Prasanna Savanor Maddu Rao
  • CYCLIC UREAS AS INHIBITORS OF ROCK
    Publication number: 20180000788
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: January 8, 2016
    Publication date: January 4, 2018
    Inventors: Peter W. Glunz, Doree F. Sitkoff, Navnath Dnyanoba, Mandar Shrikrishna Bodas, Rajeev S. Bhide, Sharanabasappa Patil, Kumaresan Chinnakotti, Prasanna Savanor Maddu Rao
  • LXR modulators
    Patent number: 9751869
    Abstract: The present invention provides compounds of Formula I and Formula II: or pharmaceutically acceptable salts or solvates thereof, as modulators of liver X receptors (LXRs), and compositions comprising any of such novel compounds and methods of use thereof. These compounds are useful as medicaments for treatment and/or prophylaxis for diseases or conditions related to activity of LXRs.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 5, 2017
    Assignees: Bristol-Myers Squibb Company, Exelixis Patent Company LLC
    Inventors: Ellen K. Kick, Mandar Bodas, Raju Mohan, Brett B. Busch, Claudia Averbuj, Meriah Valente, Nicholas Wurtz, Prasanna Savanor Maddu Rao, Jeevanprakash Shetty, Alla Venu
  • LXR MODULATORS
    Publication number: 20160289222
    Abstract: The present invention provides compounds of Formula I and Formula II: or pharmaceutically acceptable salts or solvates thereof, as modulators of liver X receptors (LXRs), and compositions comprising any of such novel compounds and methods of use thereof. These compounds are useful as medicaments for treatment and/or prophylaxis for diseases or conditions related to activity of LXRs.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 6, 2016
    Applicants: BRISTOL-MYERS SQUIBB COMPANY, EXELIXIS PATENT COMPANY LLC
    Inventors: Ellen K. Kick, Mandar Bodas, Raju Mohan, Brett B. Busch, Claudia Averbuj, Meriah Valente, Nicholas Wurtz, Prasanna Savanor Maddu Rao, Jeevanprakash Shetty, Alla Venu